HSP90 as a new therapeutic target for cancer therapy: The story unfolds

Expert Opinion on Biological Therapy

Volumn 2, Issue 1, 2002, Pages 3-24

  Maloney, Alison ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Apoptosis; Cancer; Cell cycle; Drug development; Geldanamycin; Heat shock protein; Signal transduction

Indexed keywords

17 ALLYLAMINO,17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CHAPERONE; COUMARIN DERIVATIVE; CYTOTOXIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; KF 25706; KF 58333; PURINE DERIVATIVE; RADICICOL; TRASTUZUMAB; TUMOR VACCINE; UNCLASSIFIED DRUG; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; MACROCYCLIC LACTAM; RIFABUTIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER INVASION; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; TOXICITY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; RIFABUTIN;

EID: 0035989680     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.1.3     Document Type: Review

References (144)

1. Role of the heat shock response and molecular chaperones in oncogenesis and cell death
2. Molecular chaperones: Biology and prospects for pharmacological intervention
3. Chaperones in signal transduction
4. Regulation of the heat shock transcriptional response: Cross talk between a family of heat shock factors, molecular chaperones, and negative regulators
5. Heat shock proteins: New keys to the development of cytoprotective therapies
6. The 90-kDa molecular chaperone family: Structure, function and clinical applications. A comprehensive review
7. Linking gene expression patterns to therapeutic groups in breast cancer
8. Do heat shock proteins have a role in breast cancer?
9. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus
10. Clinical and biological significance of HSP89a in human breast cancer
11. Unusual expression and localization of heat shock proteins in human tumor cells
12. Constitutive overexpression of 89 kDa heat shock protein gene in the HBL100 mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene
13. New drug targets for genomic cancer therapy: Successes, limitations, opportunities and future challenges
14. Scoring a bull's-eye against cancer genome targets
15. Changing times: Developing cancer drugs in genomeland
16. Discovering novel chemotherapeutic drugs for the third millennium
17. Hsp90: A specialized but essential protein-folding tool
18. Hsp90 & Co. - A holding for folding
19. Hsp90 as a capacitor for morphological evolution
20. The molecular chaperones Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by the glucocorticoid receptor
21. Control of estrogen receptor ligand binding by Hsp90
22. Hsp90 regulates androgen receptor hormone binding affinity
23. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent
24. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone
25. lck
26. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Weel and Swel
27. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90
28. A pathway of multi-chaperone interactions common to diverse regulatory proteins: Estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor
29. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway
30. The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors
31. Interaction between casein kinase II and the 90-kDa stress protein HSP90
32. Mammalian p50cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes CDK4
33. Modulation of AKT kinase activity by binding to Hsp90
34. Disruption of Hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-κB activation
35. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
36. Regulation of Pim-1 by Hsp90
37. Specific association of a set of molecular chaperones including HSP90 and CDC37 with MOK, a member of the mitogen-activated protein kinase family
38. Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability
39. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase
40. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network
41. Hsp90 is obligatory for the heme-regulated eIF-2α kinase to acquire and maintain an activable conformation
42. The physical association of multiple chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent
43. Localization of HSP90 binding sites in the human hepatitis polymerase
44. Stable association of hsp90 and p23, but not hsp70, with active human telomerase
45. Degradation of heterotrimeric Gα subunits via the proteosome pathway is induced by the hsp90-specific compound geldanamycin
46. Dynamic activation of endothelial nitric oxide synthase by HSP90
47. Heat shock proteins 70 and 90 increase calcineurin activity through calmodulin-dependent and independent mechanisms
48. Heat shock protein 90 (hsp90) binds in vitro to tubulin dimers and inhibits microtubule formation
49. Hypoxia-induced activation of HIF-1: Role of HIF-1α-Hsp90 interaction
50. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock
51. Identification of a protein with homology to hsp90 that binds the Type 1 turnout necrosis factor receptor
52. Post-translational disruption of the delta F508 cystic fibrosis conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes delta F508 in the rabbit reticulocyte lysate
53. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum
54. Molecular chaperone GRP94 binds to the Fanconi anemia protein and regulates its intracellular expression
55. Apoprotein B degradation is promoted by the molecular chaperone hsp90 and hsp70
56. Binding of the Aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of Hsp90
57. p53-independent association between SV40 large T antigen and the major cytosolic heat shock protein, HSP90
58. Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein
59. Grp94, an ER chaperone with protein and peptide binding properties
60. The Hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties
61. The Hsp90 complex-A super-chaperone machine as a novel drug target
62. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone
63. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent
64. Structure and in vivo function of Hsp90
65. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains
66. cdc37 acting in concert with Hsp90 is required for raf-1 function
67. cdc37 is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules
68. The co-chaperone CHIP regulates protein triage decisions mediated by heat shock proteins
69. Mutations in Hsp83 and cdc37 impair signalling by the sevenless receptor tyrosine kinase in Drosophila
70. Mice lacking HSP90β fail to develop a placental labyrinth
71. Function of 90-kDa heat shock protein in cellular differentiation of human embryonal carcinoma cells
72. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity
73. Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones
74. The hallmarks of cancer
75. Geldanamycin, a new antibiotic
76. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus
77. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamcyin binds to HSP90 and shares important biologic activities with geldanamycin
78. Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent
79. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
80. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo
81. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
82. Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats
83. Geldanamycin-induced toxicity in human colon-cancer cell lines: Evidence against the involvement of c-Src or DT-diaphorase
84. Phase 1 pharmacologic study of 17-(Allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors
85. Phase 1 trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxy-geldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints
86. Phase 1 trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (Pts) with advanced solid malignancies
87. A Phase 1 trial of 17-allyl-amino-geldanamycin in patients with advanced cancer
88. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
89. Inhibition of signal transduction by 17-allylamino-7-demethoxygeldanamycin results in cytostasis and apoptosis
90. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
91. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
92. Proliferation, cell cycle and apoptosis in cancer research
93. Checking out the G2/M transition
94. Control of the cell cycle and apoptosis
95. Surfing the p53 network
96. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
97. Ansamycins cause a G2/M arrest in glioblastoma cell lines
98. Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells
99. Genetic interactions between Hsp90 and the cdc2 mitotic machinery in the fission yeast Schizosaccharomyces pombe
100. Cell cycle transition under stress conditions controlled by vertebrate heat shock factors
101. A gene expression database for the molecular pharmacology of cancer
102. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
103. Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates
104. Polo-like kinase-1 is a target of the DNA damage checkpoint
105. Escaping cell death: Survival proteins in cancer
106. Heat shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome
107. Negative regulation of the Apaf-1 apoptosome by Hsp70
108. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90
109. Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks FAS/APO-1 and staurosporine induced cell death
110. Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance
111. Acquired thermotolerance following heat shock protein synthesis prevents impairment of mitochondrial ATPase activity at elevated temperature in Sacchromyces cerevisiae
112. Mitochondria are selective target for the protective effects of heat shock against oxidative injury
113. Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth
114. Angiogenesis in cancer and other diseases
115. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumour angiogenesis and therapeutics
116. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase
117. Validation of pharmacodynamic endpoints for the Hsp90 molecular chaperone inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in a human tumor xenograft model
118. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90-binding agents
119. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamcyin (NSC 330507) in CD2F1 micel
120. Heat shock protein expression independently predicts clinical outcome in prostate cancer
121. Overexpression of heat shock proteins in carcinogenic endometrium
122. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB-and schedule-dependent manner
123. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters
124. Destabilization of receptors by heat shock protein 90-binding drugs: A ligand-independent approach to hormonal therapy of breast cancer
125. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations
126. Inhibition of the oncogene product p185erbB2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives
127. erbB2 oncogene inhibition by geldanamycin derivatives: Synthesis, mechanism of action, and structure-activity relationships
128. Structure-activity relationships of the Hsp90 inhibitor 17-allylamino 17-demethoxy geldanamycin analogues (17AAG)
129. Gene expression profiling of an ovarian tumour cell line to determine 'on-target' and 'off-target' effects of HSP90 inhibitors
130. Radicicol, an agent inducing the reversal of transformed phenotype of src-transformed fibroblasts
131. Suppression of RAS and MOS transformation by radicicol
132. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamcyin
133. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin
134. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones
135. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules
136. The interaction of coumarin antibiotics with fragments of gyrase B protein
137. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone
138. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins
139. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
140. Assays for HSP90 and inhibitors
141. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
142. Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines
143. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines